External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

2023 GU Cancers Symposium

February 16 - February 18

San Francisco, USA/ Virtual (Hybrid)

conferences.asco.org

Add to calendar

Medical Materials

Agenda

Coming soon

02:00 PM

Duration 90mins Level 3 Ballroom

Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study

Bamias A., Davis I.D., Galsky M., Arija J.A.A., Kikuchi E., Grande E., Garcia del Muro X., Park S.E., De Giorgi U., Alekseev B., Mencinger M. Izumi K., Vazquez J.P., Li J.R., Tchaleu F.B., Mariathasan S., Lee C., Bernhard S., De Santis M.

Oncology | Urogenital Cancer

Add to calendar

Duration 90mins Level 3 Ballroom

Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): final OS from the randomized Ph III IMvigor130 study

Galsky M., Arija J.A.A., De Santis M., Davis I.D., Bamias A. Kikuchi E., Garcia del Muro X., Park S.H., De Giorgi U., Alekseev B. Mencinger M., Izumi K., Vazquez J.P., Li J.R., O'Donnell P. Bernhard S., Lee C.,Tchaleu F.B., Mariathasan S., Grande E.

Oncology | Urogenital Cancer

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.